Clear Vascular, Inc.

Clear Vascular, Inc. (CVI) is a clinical stage company established in 2005 by Dr. Gilbert Gonzales, the CEO. The company has received equity and equity-sparing funding to pursue its goals of imaging and treating vulnerable plaque and other vascular inflammatory diseases. CVI has developed tin-117m based products in collaboration with the US Department of Energy and Brookhaven National Laboratory under the Initiative for Proliferation Prevention (IPP) program.